Cygnus Capital Advisors LLC Reduces Stock Holdings in Pfizer Inc. $PFE

Cygnus Capital Advisors LLC lessened its position in shares of Pfizer Inc. (NYSE:PFE) by 26.8% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 104,460 shares of the biopharmaceutical company’s stock after selling 38,340 shares during the quarter. Pfizer makes up about 1.7% of Cygnus Capital Advisors LLC’s holdings, making the stock its 25th largest position. Cygnus Capital Advisors LLC’s holdings in Pfizer were worth $2,515,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in PFE. Angeles Wealth Management LLC grew its position in Pfizer by 2.2% during the second quarter. Angeles Wealth Management LLC now owns 17,009 shares of the biopharmaceutical company’s stock worth $410,000 after buying an additional 358 shares in the last quarter. Manchester Financial Inc. lifted its position in shares of Pfizer by 2.9% in the 2nd quarter. Manchester Financial Inc. now owns 13,168 shares of the biopharmaceutical company’s stock worth $317,000 after acquiring an additional 365 shares during the period. Vermillion Wealth Management Inc. lifted its position in shares of Pfizer by 19.4% in the 1st quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock worth $66,000 after acquiring an additional 382 shares during the period. Eagle Capital Management LLC grew its holdings in shares of Pfizer by 0.3% during the 1st quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock worth $3,554,000 after purchasing an additional 390 shares in the last quarter. Finally, Delta Financial Advisors LLC increased its position in shares of Pfizer by 1.6% during the first quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock valued at $709,000 after purchasing an additional 398 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Trading Down 0.1%

PFE stock opened at $28.42 on Tuesday. The business has a fifty day moving average price of $26.06 and a 200 day moving average price of $26.34. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. Pfizer Inc. has a fifty-two week low of $23.58 and a fifty-two week high of $29.21. The stock has a market capitalization of $161.98 billion, a price-to-earnings ratio of 37.40, a P/E/G ratio of 1.91 and a beta of 0.34.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The company had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the previous year, the firm earned $0.78 earnings per share. The business’s revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts expect that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th were paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.1%. The ex-dividend date of this dividend was Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is 226.32%.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on PFE. BMO Capital Markets cut their target price on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. HSBC cut shares of Pfizer from a “buy” rating to a “hold” rating and dropped their price objective for the company from $32.00 to $28.00 in a research note on Monday, July 6th. JPMorgan Chase & Co. decreased their target price on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 8th. UBS Group reissued a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research note on Wednesday, May 27th. Finally, Guggenheim dropped their price target on shares of Pfizer from $35.00 to $31.00 and set a “buy” rating for the company in a research report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $28.28.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.